Coenzyme Q10 + alpha lipoic acid for chronic COVID syndrome
Barletta MA, Marino G, Spagnolo B, Bianchi FP
Published in Clinical and Experimental Medicine
Methodology
Prospective observational study of 174 patients with chronic COVID syndrome: 116 received coenzyme Q10 plus alpha lipoic acid and 58 received no treatment, with change in Fatigue Severity Scale as the primary outcome
Key Findings
A complete Fatigue Severity Scale response was reached in 62 (53.5%) treated patients versus 2 (3.5%) untreated controls.
Conclusions
Mitochondrial nutrients may help post-viral fatigue, but the non-randomised design means the effect size is likely inflated.
Limitations
Observational, unblinded, no placebo control, single product studied.
Supplements Studied
A FSS complete response was reached in 62 (53.5%) patients in treatment group and in two (3.5%) patients in control group.
A FSS complete response was reached in 62 (53.5%) patients in treatment group and in two (3.5%) patients in control group.
Outcomes Measured
A FSS complete response was reached in 62 (53.5%) patients in treatment group and in two (3.5%) patients in control group.
Study Details
Access Study
Disclosures
Funding
Product-linked observational study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.